Stay in the loop! Subscribe to our newsletter and gain access to exclusive insights, trends, and news from the world of business and leadership. Don’t miss out!
A Union Jack–lit Manhattan skyscraper, British nobility, celebrities, and JPMorgan’s top brass come together for an unexpected royal birthday tribute. A Royal Celebration—Without the King—Lights Up Manhattan In a scene more reminiscent of London’s Mayfair than Midtown Manhattan, JPMorgan Chase CEO Jamie Dimon hosted
Humanized Leadership: Looking Beyond the Badge In a world where organizations often
In a market driven by ambition and constant reinvention, Denis Donovan has
With the global speaking industry valued at over $2 billion and growing
A Historic Transaction in Publishing In a move that has captured the
Republican Senator Rick Scott on Wednesday raised concerns with Intel CEO Pat Gelsinger regarding the company’s plans to cut more than 15,000
Hindenburg Research, known for its impactful short-selling reports, has disclosed a short position in Super Micro Computer, a leading AI server maker.
Chinese electric vehicle (EV) giant BYD has announced a partnership with Huawei to integrate the tech conglomerate’s advanced autonomous driving system into
After its unsuccessful attempt to acquire Anglo American, BHP Group has indicated a strong commitment to expanding its copper business through existing
On Wednesday, Nvidia is likely to report that its second-quarter revenue more than doubled. However, investors accustomed to the company’s blockbuster results
Australia’s leading independent gas producer, Woodside Energy, is set to announce a decline in interim earnings on Tuesday. Investors are closely watching
China Petroleum & Chemical Corp, commonly known as Sinopec, announced a 2.6% increase in net profit for the first half of the
Nestlé’s Chairman Paul Bulcke has affirmed the company’s intention to retain its Health Science unit, countering speculation about a potential sale. In
According to recent reports, Eli Lilly’s promising Alzheimer’s treatment, donanemab, may be blocked for use by Britain’s National Health Service (NHS). The
Johnson & Johnson (J&J) is currently negotiating with plaintiffs’ lawyers who have opposed the company’s proposed $6.48 billion settlement of lawsuits alleging
